Lower Respiratory Tract Infection Antibiotic Guidelines

Outpatient Community-Acquired LRTI (Including Acute Bronchitis and Mild CAP)

For uncomplicated lower respiratory tract infections managed at home, amoxicillin or doxycycline should be prescribed as first-line therapy for 5-7 days, with patients instructed to return if fever persists beyond 48 hours. 1, 2, 3

First-Line Antibiotic Selection

Amoxicillin is the preferred first-choice agent for home-managed LRTI, providing coverage against Streptococcus pneumoniae, the most frequently encountered pathogen 1
Doxycycline is equally recommended as first-line therapy due to its proven efficacy, extensive clinical experience, low cost, and coverage of both typical and atypical pathogens including Mycoplasma pneumoniae 3
Doxycycline has the specific advantage of covering atypical pathogens, making it particularly valuable during M. pneumoniae epidemics or in young adults with nonsevere disease 3

Alternative Agents (Second-Line)

Co-amoxiclav (amoxicillin-clavulanate) should be used when there is high frequency of beta-lactamase-producing Haemophilus influenzae in the area, chronic lung disease, recent treatment failure with aminopenicillin, or documented resistance 1
Macrolides (erythromycin, clarithromycin, azithromycin) are alternatives for patients with hypersensitivity to preferred drugs or in areas with widespread clinically relevant resistance 1
Levofloxacin or moxifloxacin should be reserved as second-line or alternative therapy only in specific clinical scenarios such as clinically relevant bacterial resistance to first-line agents, treatment failure, or major intolerance to first-line agents 1, 3
Fluoroquinolones should NOT be used as first-line agents due to antimicrobial stewardship concerns regarding resistance development in the community 3

Treatment Duration and Monitoring

Standard duration is 5-7 days for uncomplicated LRTI 1, 2
Patients should be instructed to return if fever does not resolve within 48 hours or if symptoms persist beyond 3 weeks 2, 3
Clinical improvement is expected within 3 days of starting antibiotics 2, 3
Cough may last longer than the duration of antibiotic treatment, and this should be explained to patients 1

Critical Pitfall: Antibiotic Overuse

Most lower respiratory tract infections are viral in origin and will not benefit from antibiotic therapy 4
Antibiotics should NOT be prescribed for viral bronchitis in otherwise healthy adults, as most LRTI are self-limiting 2
Recent prospective data show that a bacterial pathogen is identified in only approximately one in five adult patients with LRTI in primary care, with viral pathogens detected in just under half 5
Do not extend treatment beyond 7 days for uncomplicated LRTI without specific indication, as this increases adverse effects without improving outcomes 2

Community-Acquired Pneumonia (CAP) Requiring Hospitalization

For hospitalized patients with nonsevere CAP, prescribe penicillin G or a 2nd/3rd generation cephalosporin PLUS a macrolide; for severe CAP, use a 3rd generation cephalosporin PLUS a macrolide for a minimum of 5 days. 1, 2

Nonsevere CAP (Hospitalized but Not ICU)

Penicillin G + macrolide is the preferred regimen 1
Aminopenicillin + macrolide is an alternative combination 1
Co-amoxiclav + macrolide is an alternative combination 1
2nd or 3rd generation cephalosporin + macrolide is an alternative combination 1
Levofloxacin or moxifloxacin monotherapy is recommended for hospitalized patients with moderate to severe CAP where fluoroquinolone therapy is guideline-recommended 1, 3

Severe CAP (ICU or Meeting Severity Criteria)

Severe CAP is defined by the presence of at least two of the following: systolic blood pressure <90 mmHg, severe respiratory failure (PaO₂/FiO₂ <250), multilobar involvement on chest radiograph, requirement for mechanical ventilation, or requirement for vasopressors. 1

3rd generation cephalosporin + macrolide is the preferred regimen for severe CAP 1
3rd generation cephalosporin + (levofloxacin or moxifloxacin) is an alternative combination 1

Severe CAP with Pseudomonas Risk Factors

For severe CAP with risk factors for Pseudomonas aeruginosa, use an antipseudomonal cephalosporin OR acylureidopenicillin/β-lactamase inhibitor + ciprofloxacin OR carbapenem + ciprofloxacin. 1

Risk factors for Pseudomonas include:

Structural lung disease (bronchiectasis, cystic fibrosis) 6
Recent hospital admission 6
Recent or frequent antibiotic use 6
Severe airflow limitation (FEV₁ <50% predicted) 6
Prior isolation of P. aeruginosa 6

Treatment Duration and IV-to-Oral Switch

Minimum of 5 days of therapy is recommended for CAP, with treatment extending beyond 5 days only if the patient has not achieved clinical stability 2
Switch from IV to oral therapy should occur by day 3 if the patient is clinically stable (temperature <37.8°C, HR <100, RR <24, SBP >90, O₂ sat >90%) 2, 6
Hospitalized patients should be reassessed at day 2-3 for clinical response, including fever resolution and lack of progression of pulmonary infiltrates 2

Extended Duration for Specific Pathogens

Legionella pneumophila: 21 days with a macrolide plus rifampicin 2
Staphylococcus aureus and Gram-negative enteric bacilli: 14-21 days 2

Acute Exacerbations of COPD (AECOPD)

For mild COPD exacerbations, prescribe amoxicillin or doxycycline; for moderate/severe exacerbations, use co-amoxiclav; for COPD with Pseudomonas risk factors, use ciprofloxacin 750 mg PO twice daily for 14 days. 1, 3, 6

When to Prescribe Antibiotics in AECOPD

Antibiotics are indicated only for Type I Anthonisen exacerbations (increased dyspnea, sputum volume, AND sputum purulence) or Type II with purulence 2
Do NOT use prophylactic antibiotics in patients with chronic bronchitis or COPD for prevention of exacerbations 2

Antibiotic Selection by Severity

Mild COPD exacerbations:

Amoxicillin or doxycycline 1
Alternatives: co-amoxiclav, macrolides, levofloxacin, moxifloxacin 1

Moderate/Severe COPD exacerbations (hospitalized):

Co-amoxiclav is the preferred agent 1
Alternatives: levofloxacin, moxifloxacin 1, 3

COPD with Pseudomonas risk factors:

Ciprofloxacin 750 mg PO twice daily for 14 days is the oral antibiotic of choice when Pseudomonas coverage is needed 6
For hospitalized patients with severe COPD exacerbations and Pseudomonas risk, ciprofloxacin is recommended 1, 3

Treatment Duration

5 days of antibiotic therapy is recommended for COPD exacerbations with bacterial infection, with treatment not exceeding 8 days in a responding patient 2
For documented Pseudomonas respiratory infections, 14 days is preferred 6

Monitoring and Reassessment

Outpatient patients should be reassessed at day 5-7 if no improvement 2
Fever should resolve within 2-3 days after initiating treatment 2
After 3 days without improvement, consider alternative diagnoses or complications rather than automatically extending antibiotic duration 2

Bronchiectasis

For bronchiectasis exacerbations without Pseudomonas risk factors, use amoxicillin-clavulanate, levofloxacin, or moxifloxacin; for bronchiectasis with Pseudomonas risk factors, use ciprofloxacin 750 mg PO twice daily for 14 days. 1, 6

Antibiotic Selection

No Pseudomonas risk factors:

Amoxicillin-clavulanate 1
Levofloxacin 1
Moxifloxacin 1

Pseudomonas risk factors present:

Ciprofloxacin 750 mg PO twice daily for 14 days is the standard oral regimen 6
Intravenous antibiotics should be considered when patients are particularly unwell, have resistant organisms, or have failed to respond to oral therapy 6
For severe infections or treatment failures, combination therapy with an antipseudomonal β-lactam plus ciprofloxacin or an aminoglycoside is recommended 6

Critical Pitfalls

Never assume lower doses or shorter durations are adequate for Pseudomonas 6
Stopping at 12 days instead of 14 days increases risk of relapse and resistance 6
Obtain sputum culture before starting antibiotics to confirm susceptibility and guide therapy 6
Never extend oral ciprofloxacin monotherapy beyond 14 days, as this promotes resistance without proven benefit 6

Pseudomonas aeruginosa Coverage: Detailed Guidance

Oral Therapy for Pseudomonas

Ciprofloxacin 750 mg PO twice daily is the ONLY reliable oral antibiotic for Pseudomonas aeruginosa coverage; moxifloxacin and gemifloxacin do NOT provide adequate antipseudomonal activity. 6

Ciprofloxacin provides superior tissue penetration and antipseudomonal activity compared with all other oral fluoroquinolones 6
Levofloxacin 750 mg PO daily can be used as a second-line option, though it is less potent against Pseudomonas than ciprofloxacin 6
Standard treatment duration is 14 days for documented Pseudomonas respiratory infections 6

Intravenous Therapy for Pseudomonas

For severe Pseudomonas infections, use an antipseudomonal β-lactam (piperacillin-tazobactam, ceftazidime, cefepime, or meropenem) PLUS either ciprofloxacin 400 mg IV every 8 hours OR an aminoglycoside (tobramycin preferred). 6

First-line antipseudomonal β-lactams:

Piperacillin-tazobactam 4.5 g IV every 6 hours (use prolonged 4-hour infusion for critically ill patients) 6
Ceftazidime 2 g IV every 8 hours 6
Cefepime 2 g IV every 8 hours 6
Meropenem 1 g IV every 8 hours (superior carbapenem with documented activity against P. aeruginosa) 6

Second agent options for combination therapy:

Ciprofloxacin 400 mg IV every 8 hours (preferred fluoroquinolone for antipseudomonal therapy) 6
Tobramycin 5-7 mg/kg IV daily (preferred aminoglycoside due to lower nephrotoxicity than gentamicin; target peak 25-35 µg/mL, trough <2 µg/mL) 6
Amikacin 15-20 mg/kg IV daily (alternative aminoglycoside) 6

For severe β-lactam allergy:

Aztreonam 2 g IV every 8 hours is the only antipseudomonal β-lactam option for patients with severe penicillin allergy 6

When Combination Therapy is Mandatory

Combination therapy with an antipseudomonal β-lactam PLUS either ciprofloxacin or an aminoglycoside is required for: 6

ICU admission or septic shock
Ventilator-associated or nosocomial pneumonia
Structural lung disease (bronchiectasis, cystic fibrosis)
Prior IV antibiotic use within 90 days
Documented Pseudomonas on Gram stain
High local prevalence of multidrug-resistant strains

Antibiotics That Do NOT Cover Pseudomonas

Critical pitfall: The following antibiotics have NO activity against Pseudomonas aeruginosa and should NEVER be used when antipseudomonal coverage is required: 6

Ceftriaxone 6
Cefazolin 6
Ampicillin-sulbactam 6
Ertapenem 6
Cefdinir and all other oral cephalosporins 6
Most streptococcal-focused and enterococcal agents 6

Treatment Duration and De-escalation

Standard duration is 7-14 days depending on infection site and severity 6
Once susceptibility results are available and the patient is improving, therapy can be narrowed to monotherapy if the organism is susceptible 6
Consider de-escalation to monotherapy once susceptibility results are available if the patient is improving 6

Inhaled Therapy for Chronic Pseudomonas Colonization

Tobramycin 300 mg inhaled twice daily is recommended as maintenance therapy for cystic fibrosis patients or chronic bronchiectasis with P. aeruginosa colonization 6
Colistin 1-2 million units inhaled twice daily is an alternative inhaled agent 6

Special Considerations

Penicillin Allergy

For non-Type I hypersensitivity reactions, cephalosporins can be considered 6
For severe reactions (anaphylaxis), avoid all β-lactams and use aztreonam for Pseudomonas coverage or fluoroquinolones for non-Pseudomonas LRTI 6
For severe β-lactam allergy with Pseudomonas infection, use levofloxacin 750 mg IV daily plus aminoglycoside (tobramycin or amikacin) 6

Renal Impairment

Aminoglycosides require therapeutic drug monitoring to optimize efficacy and minimize toxicity 6
Aminoglycosides should not be used in patients with baseline renal dysfunction (CrCl <50 mL/min) due to increased toxicity risk 6
Monitor renal function, drug levels, and auditory function when using aminoglycosides 6
Dose adjustments are required for most antipseudomonal agents in renal impairment 6

Local Resistance Patterns

Antibiotic selection should always be based on local resistance patterns 1
Recent data show that penicillin-resistant pneumococci and β-lactamase-producing H. influenzae are uncommon in Europe, supporting a restrictive approach to antibiotic prescribing and the use of first-line, narrow-spectrum agents 5
Regular monitoring of susceptibility patterns is recommended, particularly with long-term therapy 6

Hospitalization Decision-Making

The decision to hospitalize should be validated against at least one objective tool of risk assessment 1
Both the pneumonia severity index (PSI) and the CURB index (mental confusion, urea, respiratory rate, blood pressure) are valid tools 1
In patients with a PSI of IV and V, and/or a CURB of >2, hospitalization should be seriously considered 1

Help us tailor your experience